Developer docs
API playgroundTry for free, no card

Search company profiles

PharmBioTec gGmbH

Full company profile

uuid0053mzj

Namestring
PharmBioTec gGmbH
Legal namestring
PharmBioTec gGmbH
Websiteurl
pharmbiotec.de
Company typeenum
Private
Founded yearint
2010
Short descriptiontext

PharmBioTec gGmbH is a non-profit German contract research organization specializing in preclinical pharmaceutical research using animal-free in vitro and ex vivo methods, HPLC-MS/MS proteomics, and human cell-based disease models, serving pharmaceutical companies and academic institutions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSchiffweiler, Germany
HQ citystring
Schiffweiler
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract research services, preclinical drug development, in vitro efficacy testing, pharmaceutical formulation development, animal-free testing methods
Industry2 codes
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Research Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

Fee-for-service pharmaceutical contract research including formulation development, analytical services, and in vitro testing conducted on behalf of industrial partners and research institutions.

pharmbiotec.de
2Joint Research Projects
TypeProfessional Services
Description

Collaborative research projects with partners from industry and academia, often funded by government programs (EFRE, INNO-KOM, ZIM) and aimed at developing new methods or product innovations.

pharmbiotec.de
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Infrastructure
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Services range from initial idea through method development to long-term analytical support. Pricing tailored to project scope and requirements.

pharmbiotec.de
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PharmBioTec gGmbH is a non-profit contract research organization providing preclinical pharmaceutical research services, including formulation development, in vitro efficacy and safety testing using cell and tissue models, and analytical services such as HPLC and HPLC-MS. The offering targets industrial clients in pharmaceuticals, cosmetics, and chemicals as well as academic research partners, with a particular emphasis on animal-free methods (NAMs).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Successfully published first results from EFRE-funded SaAr in vitro project in European Journal of Pharmaceutics and Biopharmaceutics (2025)
Product overview1 text field

PharmBioTec gGmbH is a non-profit contract research organization offering a portfolio of pharmaceutical research and development services. The core offerings include: (1) Non-Profit Research services focused on developing alternatives to animal testing using NAMs (New Approach Methodologies), with current projects including SaAr in vitro, MucPower, and IMPACT; (2) Formulation Development services creating innovative formulations such as inhalation systems, nasal sprays, creams, and nanocarriers; (3) In vitro Efficacy & Safety Testing using established cell and tissue models; (4) Bioequivalence Studies including permeation testing; and (5) Analytics services including HPLC-MS analyses. The company operates from the Pharmacampus in Schiffweiler, Germany, and collaborates with industry partners and academic institutions.

Product and service4 records
1Pharmaceutical Formulation Development
CategoryPharmaceutical contract research
Description

Preclinical formulation development services for pharmaceutical and cosmetics clients, supporting early-stage development of dosage forms and test articles that subsequently feed into in vitro testing programs.

2In Vitro Efficacy and Safety Testing
CategoryPreclinical contract research
Description

Animal-free in vitro testing services using cell-based models, reconstructed human skin and mucosa models, and other New Approach Methodologies (NAMs) to assess efficacy and safety of pharmaceutical, cosmetic, and chemical compounds.

3Analytical Services (HPLC and HPLC-MS)
CategoryAnalytical contract services
Description

Analytical chemistry services using HPLC and HPLC-MS, including mass spectrometry-based proteomics workflows, for compound characterization, stability studies, and bioanalytical support of preclinical research.

4Publicly Funded Collaborative Research Projects
CategoryCollaborative research services
Description

Collaborative, grant-funded research projects with universities, research institutes, and industry partners to advance animal-free testing methods, in vitro models, and analytical technologies.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
13R-Plattform Saar
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Platform for making alternative methods (3R: Replacement, Reduction, Refinement) available to other researchers.

pharmbiotec.de
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Collaborative research on neurodegenerative diseases (Alzheimer's and Parkinson's) developing selenium-containing 5-HT6R ligands as innovative treatments.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Co-located at Pharmacampus in Schiffweiler. PSM is a Contract Development and Manufacturing Organization (CDMO) providing GMP manufacturing. Companies share technical interfaces and collaborate on projects.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

EFRE cooperation project MucPower for lectin-based formulations against herpes and Pseudomonas infections, along with MucosaTec GmbH.

5MucosaTec GmbH
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Collaboration in SPRIN-D Challenge project MucBoost for broad-spectrum antivirals. PharmBioTec responsible for formulation development using animal-free methods. MucosaTec has labs in Berlin (development/manufacturing) and Schiffweiler (analytics & formulation development).

pharmbiotec.de
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

EU-funded collaborative research project on green chemistry and drug development. Project focuses on integrating environmentally friendly chemical processes into innovative drug development with minimal environmental impact.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Academic partner in multinational research collaboration on neurodegenerative diseases and other drug development projects. PharmBioTec originated as spin-off from this university.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Met at ISAM Congress 2023, one of several industry connections established during conference participation.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Met at ISAM Congress 2023, one of several industry connections established during conference participation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Academic collaboration with Prof. Daniel Lauster's team on SPRIN-D MucBoost project and other initiatives.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Met at ISAM Congress 2023, one of several industry and research connections established during conference participation.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Swiss 3D cell model company providing in vitro liver, pancreatic and other microtissue assays for preclinical drug testing. Comparable as a NAM-focused preclinical CRO serving pharma with proprietary cell-based disease models.

TypeDirect peer
Description

US organ-on-chip CRO commercializing the Emulate platform for in vitro disease modeling and drug testing. Comparable as a NAM-focused preclinical CRO with proprietary cell-based disease models used by pharma.

3Kirkstall Ltd
TypeDirect peer
Description

UK-based company developing organ-on-chip and in vitro cell culture systems for preclinical drug testing, with a strong 3R alternative-testing orientation. Highly comparable as a NAM-focused preclinical testing provider serving pharma customers.

TypeBroad incumbent
Description

Large global CRO offering preclinical research services including safety assessment, discovery and research models. Operates broadly across the same preclinical CRO category as PharmBioTec but at vastly greater scale and with a wider portfolio beyond NAMs.

5CN Bio Innovations
TypeDirect peer
Description

UK organ-on-chip company offering single- and multi-organ microphysiological systems for preclinical drug development, including lung and intestinal models. Direct peer in the NAM/organ-on-chip preclinical testing space.

TypeDirect peer
Description

Dutch organ-on-chip company commercializing the OrganoPlate platform for preclinical drug development and disease modeling. Comparable as a NAM-focused European CRO with proprietary in vitro disease modeling technology.

TypeDirect peer
Description

Berlin-based multi-organ-chip company developing microphysiological systems for preclinical drug testing and 3R-aligned research. Comparable as a German/European NAM CRO with overlapping lung and intestinal modeling focus.

TypeDirect peer
Description

Hamburg-based global contract research organization offering preclinical drug discovery services including in vitro and alternative testing models. Closely comparable business model and customer base (pharma industry) to PharmBioTec, with overlapping focus on early-stage R&D services.

TypeDirect peer
Description

Danish preclinical CRO providing in vitro pharmacology, cell-based assays and molecular biology services to pharma. Comparable as a smaller specialized European CRO with NAM-aligned in vitro service offerings.

TypeDirect peer
Description

US preclinical CRO providing drug discovery, safety assessment and research models, with explicit investments in NAMs and 3R-aligned in vitro assays. Directly comparable as a preclinical CRO serving pharma with alternative testing capabilities.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmBioTec gGmbH

Pharmaceutical Contract Research Servicespharmbiotec.de

PharmBioTec gGmbH is a non-profit German contract research organization specializing in preclinical pharmaceutical research using animal-free in vitro and ex vivo methods, HPLC-MS/MS proteomics, and human cell-based disease models, serving pharmaceutical companies and academic institutions.

PharmBioTec gGmbH firmographics

Firmographics
Name
PharmBioTec gGmbH
Legal name
PharmBioTec gGmbH
Website
https://pharmbiotec.de
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
1–10 employees
Short description
PharmBioTec gGmbH is a non-profit German contract research organization specializing in preclinical pharmaceutical research using animal-free in vitro and ex vivo methods, HPLC-MS/MS proteomics, and human cell-based disease models, serving pharmaceutical companies and academic institutions.
Ownership category
akta.pro rank

PharmBioTec gGmbH industry classification

Industry
Product category
Pharmaceutical Contract Research Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Contract research services
  • Preclinical drug development
  • In vitro efficacy testing
  • Pharmaceutical formulation development
  • Animal-free testing methods

Where PharmBioTec gGmbH is headquartered

Location

Headquarters

HQ city
Schiffweiler
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

PharmBioTec gGmbH business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

  1. Contract Research Services: Fee-for-service pharmaceutical contract research including formulation development, analytical services, and in vitro testing conducted on behalf of industrial partners and research institutions.
  2. Joint Research Projects: Collaborative research projects with partners from industry and academia, often funded by government programs (EFRE, INNO-KOM, ZIM) and aimed at developing new methods or product innovations.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

PharmBioTec gGmbH product offering

Product offering

Core offering

PharmBioTec gGmbH is a non-profit contract research organization providing preclinical pharmaceutical research services, including formulation development, in vitro efficacy and safety testing using cell and tissue models, and analytical services such as HPLC and HPLC-MS. The offering targets industrial clients in pharmaceuticals, cosmetics, and chemicals as well as academic research partners, with a particular emphasis on animal-free methods (NAMs).

Product overview

PharmBioTec gGmbH is a non-profit contract research organization offering a portfolio of pharmaceutical research and development services. The core offerings include: (1) Non-Profit Research services focused on developing alternatives to animal testing using NAMs (New Approach Methodologies), with current projects including SaAr in vitro, MucPower, and IMPACT; (2) Formulation Development services creating innovative formulations such as inhalation systems, nasal sprays, creams, and nanocarriers; (3) In vitro Efficacy & Safety Testing using established cell and tissue models; (4) Bioequivalence Studies including permeation testing; and (5) Analytics services including HPLC-MS analyses. The company operates from the Pharmacampus in Schiffweiler, Germany, and collaborates with industry partners and academic institutions.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmaceutical Formulation Development Preclinical formulation development services for pharmaceutical and cosmetics clients, supporting early-stage development of dosage forms and test articles that subsequently feed into in vitro testing programs.
  • In Vitro Efficacy and Safety Testing Animal-free in vitro testing services using cell-based models, reconstructed human skin and mucosa models, and other New Approach Methodologies (NAMs) to assess efficacy and safety of pharmaceutical, cosmetic, and chemical compounds.
  • Analytical Services (HPLC and HPLC-MS) Analytical chemistry services using HPLC and HPLC-MS, including mass spectrometry-based proteomics workflows, for compound characterization, stability studies, and bioanalytical support of preclinical research.
  • Publicly Funded Collaborative Research Projects Collaborative, grant-funded research projects with universities, research institutes, and industry partners to advance animal-free testing methods, in vitro models, and analytical technologies.

Quantifiable outcome

  • Successfully published first results from EFRE-funded SaAr in vitro project in European Journal of Pharmaceutics and Biopharmaceutics (2025)

Companies that use PharmBioTec gGmbH

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

PharmBioTec gGmbH technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

PharmBioTec gGmbH partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered minor and core.

  • 3R-Plattform SaarminorStrategic or Co-development Partner · 1 January 2025Platform for making alternative methods (3R: Replacement, Reduction, Refinement) available to other researchers.
  • Jagiellonian University PolandcoreStrategic or Co-development Partner · 1 January 2024Collaborative research on neurodegenerative diseases (Alzheimer's and Parkinson's) developing selenium-containing 5-HT6R ligands as innovative treatments.
  • PSM GmbHcoreStrategic or Co-development Partner · 1 January 2024Co-located at Pharmacampus in Schiffweiler. PSM is a Contract Development and Manufacturing Organization (CDMO) providing GMP manufacturing. Companies share technical interfaces and collaborate on projects.
  • FU Berlin (Prof. Daniel Lauster)coreStrategic or Co-development Partner · 1 January 2024EFRE cooperation project MucPower for lectin-based formulations against herpes and Pseudomonas infections, along with MucosaTec GmbH.
  • MucosaTec GmbHcoreStrategic or Co-development Partner · 1 January 2023Collaboration in SPRIN-D Challenge project MucBoost for broad-spectrum antivirals. PharmBioTec responsible for formulation development using animal-free methods. MucosaTec has labs in Berlin (development/manufacturing) and Schiffweiler (analytics & formulation development).
  • Sapienza University RomecoreStrategic or Co-development Partner · 1 January 2023EU-funded collaborative research project on green chemistry and drug development. Project focuses on integrating environmentally friendly chemical processes into innovative drug development with minimal environmental impact.
  • Universität des SaarlandescoreStrategic or Co-development Partner · 1 January 2023Academic partner in multinational research collaboration on neurodegenerative diseases and other drug development projects. PharmBioTec originated as spin-off from this university.
  • MannKind Corp.minorStrategic or Co-development Partner · 1 January 2023Met at ISAM Congress 2023, one of several industry connections established during conference participation.
  • VITROCELL SystemsminorStrategic or Co-development Partner · 1 January 2023Met at ISAM Congress 2023, one of several industry connections established during conference participation.
  • Free University of BerlincoreStrategic or Co-development Partner · 1 January 2023Academic collaboration with Prof. Daniel Lauster's team on SPRIN-D MucBoost project and other initiatives.
  • Helmholtz Institute for Pharmaceutical Research SaarlandminorStrategic or Co-development Partner · 1 January 2023Met at ISAM Congress 2023, one of several industry and research connections established during conference participation.

Scale indicators3 records

Recent moves9 records

Expansion highlights6 records

PharmBioTec gGmbH competitors and assessment

Company assessment

Direct peers

  • InSphero AG: Swiss 3D cell model company providing in vitro liver, pancreatic and other microtissue assays for preclinical drug testing. Comparable as a NAM-focused preclinical CRO serving pharma with proprietary cell-based disease models.
  • Emulate, Inc. US organ-on-chip CRO commercializing the Emulate platform for in vitro disease modeling and drug testing. Comparable as a NAM-focused preclinical CRO with proprietary cell-based disease models used by pharma.
  • Kirkstall Ltd: UK-based company developing organ-on-chip and in vitro cell culture systems for preclinical drug testing, with a strong 3R alternative-testing orientation. Highly comparable as a NAM-focused preclinical testing provider serving pharma customers.
  • CN Bio Innovations: UK organ-on-chip company offering single- and multi-organ microphysiological systems for preclinical drug development, including lung and intestinal models. Direct peer in the NAM/organ-on-chip preclinical testing space.
  • Mimetas B.V. Dutch organ-on-chip company commercializing the OrganoPlate platform for preclinical drug development and disease modeling. Comparable as a NAM-focused European CRO with proprietary in vitro disease modeling technology.
  • TissUse GmbH: Berlin-based multi-organ-chip company developing microphysiological systems for preclinical drug testing and 3R-aligned research. Comparable as a German/European NAM CRO with overlapping lung and intestinal modeling focus.
  • Evotec SE: Hamburg-based global contract research organization offering preclinical drug discovery services including in vitro and alternative testing models. Closely comparable business model and customer base (pharma industry) to PharmBioTec, with overlapping focus on early-stage R&D services.
  • Bioneer A/S: Danish preclinical CRO providing in vitro pharmacology, cell-based assays and molecular biology services to pharma. Comparable as a smaller specialized European CRO with NAM-aligned in vitro service offerings.
  • Inotiv, Inc. US preclinical CRO providing drug discovery, safety assessment and research models, with explicit investments in NAMs and 3R-aligned in vitro assays. Directly comparable as a preclinical CRO serving pharma with alternative testing capabilities.

Broad incumbents

  • Charles River Laboratories: Large global CRO offering preclinical research services including safety assessment, discovery and research models. Operates broadly across the same preclinical CRO category as PharmBioTec but at vastly greater scale and with a wider portfolio beyond NAMs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

PharmBioTec gGmbH social profiles

Digital presence

PharmBioTec gGmbH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmBioTec gGmbH leadership team

Management profile

Number of profiles

Profiles6 records

PharmBioTec gGmbH funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmBioTec gGmbH M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmBioTec gGmbH

What does PharmBioTec gGmbH do?

PharmBioTec gGmbH is a non-profit contract research organization providing preclinical pharmaceutical research services, including formulation development, in vitro efficacy and safety testing using cell and tissue models, and analytical services such as HPLC and HPLC-MS. The offering targets industrial clients in pharmaceuticals, cosmetics, and chemicals as well as academic research partners, with a particular emphasis on animal-free methods (NAMs).

Is PharmBioTec gGmbH a public or private company?

PharmBioTec gGmbH is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was PharmBioTec gGmbH founded?

PharmBioTec gGmbH was founded in 2010. It employs 1 to 10 people.

Where is PharmBioTec gGmbH based?

PharmBioTec gGmbH is headquartered in Schiffweiler, Germany, in the Europe region.

How does PharmBioTec gGmbH make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are joint Research Projects.

Who are PharmBioTec gGmbH's main competitors?

Direct peers on record are InSphero AG, Emulate, Inc., Kirkstall Ltd, CN Bio Innovations, Mimetas B.V., TissUse GmbH, Evotec SE, Bioneer A/S and Inotiv, Inc.. Charles River Laboratories is listed as a broad incumbent.

Does PharmBioTec gGmbH have an API?

No public API is recorded for PharmBioTec gGmbH.

What industry is PharmBioTec gGmbH in?

PharmBioTec gGmbH's product category is Pharmaceutical Contract Research Services. Its primary akta.pro industry code is HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development), with a secondary code of HLAGAFAL, Formulation & Preclinical CMC Support (Nonclinical). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales